Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3TR Precision Therapy in Rheumatoid Arthritis
NL-OMON60220Phase 4Not yet recruiting
- Sponsor
- Queen Mary University of London
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sarilumab in rheumatoid arthritis (RA) (4 arms), sponsored by Queen Mary University of London. Primary endpoint: ACR50 responder status at 12 weeks. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON60220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60220.